These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30904971)

  • 1. Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient.
    Dash R; Junaid M; Mitra S; Arifuzzaman M; Hosen SMZ
    J Mol Model; 2019 Mar; 25(4):98. PubMed ID: 30904971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
    Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
    Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
    Konidala KK; Bommu UD; Pabbaraju N
    J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis.
    Sharma N; Sharma M; Shakeel E; Jamal QMS; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM; Akhtar S
    Med Chem; 2018; 14(6):626-640. PubMed ID: 29663896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors.
    Ai G; Tian C; Deng D; Fida G; Chen H; Ma Y; Ding L; Gu Y
    Anticancer Drugs; 2015 Apr; 26(4):399-409. PubMed ID: 25569705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.
    Abdel-Mohsen HT; Abdullaziz MA; Kerdawy AME; Ragab FAF; Flanagan KJ; Mahmoud AEE; Ali MM; Diwani HIE; Senge MO
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32053964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular simulation studies to reveal the binding mechanisms of shikonin derivatives inhibiting VEGFR-2 kinase.
    Munni YA; Ali MC; Selsi NJ; Sultana M; Hossen M; Bipasha TH; Rahman M; Uddin MN; Hosen SMZ; Dash R
    Comput Biol Chem; 2021 Feb; 90():107414. PubMed ID: 33191109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
    Ghavamipour F; Shahangian SS; Sajedi RH; Arab SS; Mansouri K; Aghamaali MR
    FEBS J; 2014 Oct; 281(19):4479-94. PubMed ID: 25132001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach.
    Liu YZ; Wang XL; Wang XY; Yu RL; Liu DQ; Kang CM
    J Mol Model; 2016 Sep; 22(9):222. PubMed ID: 27558799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
    Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
    Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect.
    Shi L; Zhou J; Wu J; Shen Y; Li X
    Curr Med Chem; 2016; 23(10):1000-40. PubMed ID: 26860998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
    Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
    Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study.
    El-Gazzar MG; El-Hazek RM; Zaher NH; El-Ghazaly MA
    Bioorg Chem; 2019 Nov; 92():103251. PubMed ID: 31525526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.